Skip to content
Open access

Combination of 5-Aminolevulinic Acid and Indocyanine Green in Photodynamic Therapy for Squamous Cell Carcinoma: An In Vivo Study

Aug 2026 · International Journal of Molecular Sciences · Vol 27, pp. 7695 · 0 citations · 56 references
Medicine

TL;DR

The results indicated that the combined ALA+ICG-PDT approach produced the most sustained suppression of tumor growth and significantly prolonged animal survival compared with single-photosensitizer PDT, representing a promising strategy to enhance PDT efficacy for NMSC and other solid tumors.

Abstract

Photodynamic therapy (PDT) is a promising minimally invasive treatment for non-melanoma skin cancer (NMSC). Still, its clinical efficacy is limited by light attenuation and drug distribution within tumor tissue, which restricts photosensitizer activation in deeper tumor regions. PDT with 5-aminolevulinic acid (ALA) is widely used as a precursor to induce accumulation of protoporphyrin IX (PpIX), followed by red light irradiation; it is effective for superficial lesions but often fails to achieve complete tumor control in thicker tumors, contributing to long-term lesion recurrence. To address this limitation, we investigated a two-photosensitizer, two-wavelength-PDT approach that combines ALA with indocyanine green (ICG), a near-infrared (NIR)-responsive photosensitizer that can be activated at greater tissue depths. This also promotes different cellular death targets, since ALA-mediated PDT mainly induces direct tumor cell killing through apoptosis and necrosis, whereas ICG-mediated PDT may contribute to treatment effects through deeper tissue activation and vascular-associated mechanisms. In this study, a preclinical model of cutaneous squamous cell carcinoma (SCC) was used, with animals assigned to control, single-photosensitizer PDT (ALA, ICG), and combined photosensitizer PDT treatment groups. The effect of photosensitizer administration and light irradiation sequence on therapeutic efficacy was also investigated, and tumor progression and survival outcomes were monitored over time. The results indicated that the combined ALA+ICG-PDT approach produced the most sustained suppression of tumor growth and significantly prolonged animal survival compared with single-photosensitizer PDT. Importantly, these findings demonstrated a strong dependence on the sequence in which the photosensitizer and light are applied. These findings indicate that integrating photosensitizers activated at complementary wavelengths may improve treatment coverage across the tumor and partially overcome depth-related limitations associated with PDT, representing a promising strategy to enhance PDT efficacy for NMSC and other solid tumors.

Read PDF

Similar papers

Oct 2026

BODIPY photosensitizers as novel PDT agents against lung cancer cell lines A548 and H1299.

Lung cancer is one of the most commonly diagnosed and lethal cancers, affecting both men and women. While conventional treatments such as surgery, chemotherapy, and radiotherapy offer therapeutic benefits in some cases, their efficacy is often limited by side effects and the development of drug resistance. Consequently...

S. Pedro, Juliana Araújo, António Aguiar et al. · 0 citations
Open access Oct 2026

Combination chemotherapy potentiates 5-aminolevulic acid-mediated photodynamic therapy killing of patient-derived glioma stem-like cells in vitro

Abstract Background 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) is a promising therapy for glioblastoma (GBM). 5-ALA induces tumor-selective accumulation of protoporphyrin IX (PPIX). Photoactivation of PPIX induces reactive oxygen species generation and tumor cell death. Glioma stem-like cells (GSC) are hypo...

Alexa Semonche, T. Slepak, A. Pascoini et al. · 0 citations
Sep 2026

A Near-Infrared-II Antibody-Photosensitizer Conjugate for Photoimmunotherapy of Advanced Pancreatic Cancer

Pancreatic cancer (PC) is a highly lethal malignancy, characterized by frequent late-stage diagnosis and limited response to available treatments. Photoimmunotherapy, which combines the localized tumor ablation of phototherapy with the systemic immune activation of immunotherapy, presents a promising strategy. Howeve...

Ding-Yuan Yan, Jin-Xian Wu, Ye Tong et al. · 0 citations
Open access Sep 2026

Far-field bioluminescent immune cell-mediated photodynamic therapy is limited by photon flux.

No detectable ROS generation or tumor cell cytotoxicity in vitro is observed using luciferase-engineered tumor-associated macrophages and verteporfin, and complementary Monte Carlo simulations show that achievable photon fluxes are several orders of magnitude below established thresholds for cytotoxic PDT.

Ji Tae Park, Sudip Timilsina, Rebecca C. Harman et al. · 0 citations
Sep 2026

Two-photon photodynamic induction of PANoptosis and immunogenic cell death for precision tumor eradication using a dual-organelle-targeted STING agonist.

This study addresses triple-negative breast cancer treatment by developing a photosensitizer, DBC, with a multiple-twist molecular architecture, offering broader readers an impactful paradigm for engineering multi-functional biomaterials to combat aggressive cancers.

Hao Ren, Da-Lu Xie, Wen-Zhao Shang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.